Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
12,388 stopped studies mapped to Malignant Neoplasm and descendants · 89% state a reason
Over the 12,388 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03412058 | Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists(CHECK'UP) | N/A | terminated | Jan 26, 2018 | UNICANCER | The study was terminated prematurely due to insufficient patient recruitment | Enrollment / accrual |
| NCT03662074 | Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small… | Phase 2 | terminated | Sep 7, 2018 | Wake Forest University Health Sciences | After interim analysis decided not to move forward with continuing the trial. | Efficacy / futility |
| NCT03868943 | Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma(JAZZ) | Phase 2 | terminated | Mar 11, 2019 | Wake Forest University Health Sciences | Axsome has conducted a review of the ongoing IST program and are unable to continue supporting this… | Other (stated, no rule matched) |
| NCT03869190 | Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and… | Phase 1 / Phase 2 | terminated | Mar 11, 2019 | Hoffmann-La Roche | Study was closed early as the sponsor decided not to continue development of certain treatment… | Sponsor / business decision |
| NCT04646434 | Brain and Pelvic Floor Muscle Activity of Patients Who Had or Are Undergoing… | N/A | suspended | Nov 30, 2020 | Roswell Park Cancer Institute | Protocol being updates and staff trained | Other (stated, no rule matched) |
| NCT06124118 | Tumor Treating Fields for Locally Advanced NSCLC(NOVOCURE) | Phase 1 | withdrawn | Nov 9, 2023 | University of Utah | Slow accrual | Enrollment / accrual |
| NCT06221423 | Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer | — | withdrawn | Jan 24, 2024 | Fudan University | The study was withdrawn before participant enrollment because the research team decided not to… | Enrollment / accrual |
| NCT07234799 | Feasibility Testing of a Dyadic Exercise Program for Patients Undergoing Thoracic… | N/A | suspended | Nov 18, 2025 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT03287271 | ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase… | Phase 1 / Phase 2 | terminated | Sep 19, 2017 | Michael McHale | Due to loss of funding | Funding |
| NCT03796273 | Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer… | Early Phase 1 | terminated | Jan 8, 2019 | Wake Forest University Health Sciences | Low accruals | Enrollment / accrual |
| NCT05673200 | Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to… | Phase 1 | suspended | Jan 6, 2023 | National Cancer Institute (NCI) | Other - DLT assessment and phase 2 dose determination | Other (stated, no rule matched) |
| NCT05703854 | Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction… | Phase 1 / Phase 2 | suspended | Jan 30, 2023 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT06290765 | Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera(PV) | Phase 4 | withdrawn | Mar 4, 2024 | PharmaEssentia | In alignment with company strategic direction. | Sponsor / business decision |
| NCT07057089 | Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced… | Phase 2 | suspended | Jul 9, 2025 | Hebei Medical University Fourth Hospital | Suspended due to lack of drug supply: the manufacturer ceased to provide investigational drug… | Drug supply |
| NCT07377526 | TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer | Phase 1 / Phase 2 | suspended | Jan 30, 2026 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT03068403 | Dynamic Contrast Enhanced Ultrasound for Predict and Assess Rectal Cancer Response After…(RECT) | N/A | terminated | Mar 1, 2017 | University Hospital, Bordeaux | target number of inclusion not reached | Other (stated, no rule matched) |
| NCT03488225 | Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute… | Phase 2 | terminated | Apr 4, 2018 | M.D. Anderson Cancer Center | the study was closed early due to competing trials | Other (stated, no rule matched) |
| NCT04119453 | A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent… | Phase 2 | terminated | Oct 8, 2019 | Elevar Therapeutics | The RM-202 study was terminated by the Sponsor due to redirection of the rivoceranib development… | Other (stated, no rule matched) |
| NCT05747794 | Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in…(AIPAC-003) | Phase 2 / Phase 3 | terminated | Feb 28, 2023 | Immutep S.A.S. | Sponsor Decision | Sponsor / business decision |
| NCT06021600 | A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to… | Phase 1 | terminated | Sep 1, 2023 | M.D. Anderson Cancer Center | Slow participant enrollment | Enrollment / accrual |
| NCT06472726 | Mental Health App for Cancer Survivors Study(MACS) | N/A | terminated | Jun 25, 2024 | University of Wisconsin, Madison | App developer is no longer in business | Sponsor / business decision |
| NCT03031821 | Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome(PRIME) | Phase 3 | terminated | Jan 26, 2017 | Canadian Urologic Oncology Group | Manufacturer discontinued the production of study drugs. | Drug supply |
| NCT03695250 | BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver… | Phase 1 / Phase 2 | terminated | Oct 4, 2018 | Edward Kim | Funding source decision to terminate study. | Funding |
| NCT04797702 | Glumetinib Combined With Toripalimab in the Treatment of Relapsed or Metastatic Non-small…(CT32) | Phase 1 / Phase 2 | terminated | Mar 15, 2021 | Shanghai Junshi Bioscience Co., Ltd. | The company's research strategy was adjusted and the study was terminated | Sponsor / business decision |
| NCT04974944 | First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in… | Phase 2 | terminated | Jul 23, 2021 | Sun Yat-Sen University Cancer Center | No superior PFS in study group among the enrolled patients. Company R\&D strategy shifted; funding… | Enrollment / accrual |
| NCT05322577 | A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in…(FORTITUDE-103) | Phase 1 / Phase 2 | terminated | Apr 12, 2022 | Amgen | Sponsor Decision | Sponsor / business decision |
| NCT06183151 | Capillary-Venous Paired Collection(CaVe) | — | suspended | Dec 27, 2023 | Entia Ltd | Recruitment Paused for data review | Enrollment / accrual |
| NCT06622226 | A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | Phase 1 | terminated | Oct 2, 2024 | Ono Pharmaceutical Co., Ltd. | Sponsor decided to discontinue development of the compound | Sponsor / business decision |
| NCT03598608 | Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and… | Phase 1 / Phase 2 | terminated | Jul 26, 2018 | Merck Sharp & Dohme LLC | Business Reason | Sponsor / business decision |
| NCT03744715 | A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous… | Phase 2 | terminated | Nov 16, 2018 | Spectrum Pharmaceuticals, Inc | Business reasons, not related to safety. | Safety / toxicity |
| NCT01876771 | A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in… | Phase 2 | suspended | Jun 13, 2013 | AHS Cancer Control Alberta | Study closed to accrual given widespread availability of the similar marketed product,… | Enrollment / accrual |
| NCT03178123 | The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma… | Phase 2 | terminated | Jun 6, 2017 | Shanghai Junshi Bioscience Co., Ltd. | The study strategy was adjusted, and the company decided to terminate the study early | Sponsor / business decision |
| NCT03203525 | Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating… | Phase 1 | terminated | Jun 29, 2017 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT03417739 | A Phase II Study of BVD-523 in Metastatic Uveal Melanoma | Phase 2 | terminated | Jan 31, 2018 | Dana-Farber Cancer Institute | This was a Simon two stage design trial that terminated after the first stage due to lack of… | Other (stated, no rule matched) |
| NCT04364672 | Molecular Neuroimaging to Assess the Link Between Neuroinflammation and Cognitive… | Phase 1 | withdrawn | Apr 28, 2020 | University of Alabama at Birmingham | lack of recruitment and funding | Enrollment / accrual |
| NCT05616624 | ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline… | Phase 1 / Phase 2 | terminated | Nov 15, 2022 | Washington University School of Medicine | Polaris has decided to close to accrual due to low enrollment | Enrollment / accrual |
| NCT05754749 | Comparison of CE-DBT and MRI in Patients With Known Breast Lesions | Early Phase 1 | terminated | Mar 6, 2023 | UNC Lineberger Comprehensive Cancer Center | Funding unavailable | Funding |
| NCT07242690 | PET-CT Imaging With PCD-CT | N/A | suspended | Nov 21, 2025 | Medical University of South Carolina | Study team is working on contracts. | Other (stated, no rule matched) |
| NCT03835273 | Oesophagectomy and Chest Wall and Respiratory Function | — | terminated | Feb 8, 2019 | Imperial College London | Study closed before the planned recruitment target was reached because the study period ended… | Enrollment / accrual |
| NCT03941366 | Treatment of Adenocarcinoma of the Rectum With Transanal Local Excision for Complete… | N/A | terminated | May 7, 2019 | Henry Ford Health System | Lack of financial support | Funding |
| NCT05180474 | GEN1047 for Solid Tumors - First in Human (FIH) Trial | Phase 1 / Phase 2 | terminated | Jan 6, 2022 | Genmab | The Sponsor has made a strategic decision to stop the development of GEN1047. | Sponsor / business decision |
| NCT05526079 | Watchful Waiting for Complete Responders to Therapy in Rectal Cancer | N/A | terminated | Sep 2, 2022 | Henry Ford Health System | Lack of financial support | Funding |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | Phase 1 / Phase 2 | terminated | Feb 6, 2023 | NuCana plc | The NuTide:303 study was terminated at NuCana's discretion following refinement of the NUC-3373… | Sponsor / business decision |
| NCT06008483 | A Dose Finding Study to Treat Bone Tumor(s) | Phase 1 | terminated | Aug 23, 2023 | QSAM Therapeutics, Inc. | Change in development program indication | Other (stated, no rule matched) |
| NCT06022757 | Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With… | Phase 1 / Phase 2 | terminated | Sep 5, 2023 | Evopoint Biosciences Inc. | Strategic decision by Sponsor. | Sponsor / business decision |
| NCT06509919 | Application of a Novel Model Based on Plasma cfDNA Assay and MRl Imaging in the Detection… | — | suspended | Jul 19, 2024 | Shanghai Changzheng Hospital | Modifications to trial design | Other (stated, no rule matched) |
| NCT06586658 | Anti-CD70-CAR-T Cell Injection for the Treatment of Locally Advanced or… | Early Phase 1 | suspended | Sep 19, 2024 | Shanghai Changzheng Hospital | Modifications to the trial design | Other (stated, no rule matched) |
| NCT00788307 | Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate… | Phase 1 | terminated | Nov 10, 2008 | Mayo Clinic | closed early due to poor accrual | Enrollment / accrual |
| NCT02546986 | Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic… | Phase 2 | terminated | Sep 11, 2015 | Celgene | not stated | Not stated |
| NCT03065387 | Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With… | Phase 1 | terminated | Feb 27, 2017 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 3, 2026source: clinicaltrials